New therapies in development for autoimmune diseases: Their rationale for combination treatment

Springer Seminars in Immunopathology

Volumn 23, Issue 1-2, 2001, Pages 43-61

  Strand, V ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIRHEUMATIC AGENT; CELL ADHESION MOLECULE; CYTOKINE ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MATRIX METALLOPROTEINASE; METHOTREXATE; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT PLANNING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BLOCKING; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYTOKINES; DRUG THERAPY, COMBINATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0034939378     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002810100071     Document Type: Review

References (106)

1. CTLA4Ig-mediated blockade of T cell costimulation in patients with psoriasis vulgaris
2. Immunoregulatory circuits and potential treatment of connective tissue diseases
3. +T cell-B cell antibody synthesis
4. Chondroprotective effect of gene transfer of IL-10 in type I collagen-induced arthritis
5. Effect of SB273005, an orally active, non-peptide avb3 vitronectin receptor antagonist in the adjuvant arthritic rat
6. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model
7. Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebo-controlled trial
8. Combination benefit of treatment with recombinant IL-1ra and pegylated recombinant human soluble TNF-R type I on animal models of rheumatoid arthritis
9. TNF, immunity and inflammatory disease: Lessons of the past decade
10. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes
11. Prolonged survival in murine SLE by adenoviral mediated CTLA4lg gene transfer
12. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways
13. The effect of anti-CD40L on B cells in human SLE
14. Results of a phase I single dose dose escalating trial of a humanized antiCD40L monoclonal antibody (IDEC 131) in patients with SLE
15. Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis
16. Balance of IL-1 receptor antagonist/IL-1B in rheumatoid synovium and its regulation by IL-4 and IL-10
17. The role of interleukin-1 in disease
18. Gene therapy for rheumatic diseases
19. Osteoprotegerin decreases bone resorption in adjuvant arthritis in Lewis rats
20. Combining anti-IL-1 and anti-TNF treatments provides better efficacy in rat adjuvant arthritis than does either agent alone
21. Treatment of murine lupus with CTLA4lg
22. Somatic mutations in the P53 tumor suppressor gene in rheumatoid arthritis (RA) synovium
23. Immune regulation by CD40 and its ligand of p39
24. Therapeutic effects of the anti-Fas antibody on arthritis in the HTLV-1 tax transgenic mice
25. Immunotherapeutic strategies directed at the trimolecular complex
26. Targeted apoptosis of synovial neovasculature in murine collagen induced arthritis
27. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects
28. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-Lpr mouse model
29. A proinflammatory role for IL-18 in rheumatoid arthritis
30. The CD40 ligand expressed by human B cells co-stimulates B cell responses
31. +T cell responses
32. IL-10 production and apoptosis in SLE patients and their spouses in icelandic SLE-multicase families
33. Transplantation of anergic histoincompatible bone marrow allografts
34. Immunization with T cell receptor Vb chain peptides deletes pathogenic T cells and prevents the induction of collagen-induced arthritis in mice
35. Important immunoregulatory role of IL-11 in the inflammatory process in RA
36. ICAM-1 dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats
37. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice
38. Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules
39. Role of IL-4 and IL-10 in murine collagen induced arthritis: Protective effect of IL-4 and IL-10 treatment on cartilage destruction
40. The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis
41. Oral collagen in the treatment of rheumatoid arthritis
42. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: Preservation of kidney function
43. Treatment of SLE by inhibition of T cell costimulation
44. Inhibitory effects of interleukin-10 in rheumatoid arthritis
45. Interleukin 10 expression and chemokine regulation during the evolution of murine type II collagen induced arthritis
46. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody therapy in early rheumatoid arthritis
47. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule-1
48. Angiogenesis: Implications for rheumatoid arthritis
49. IL-18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both
50. CD28/B7 system of T cell co-stimulation
51. Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus
52. Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus
53. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen induced arthritis prevents cartilage destruction
54. Viral IL-10 gene therapy inhibits collagen-induced arthritis in mice
55. HuIL-10 in subjects with active rheumatoid arthritis (RA): A phase I and cytokine response study
56. A pilot study of ISIS 2302: An antisense nucleotide in patients with active RA
57. Blockade of IL-12 during the induction of collagen-induced arthritis markedly attenuates the severity of the arthritis
58. Complement-specific antibodies: Designing novel anti-inflammatories
59. Results of a phase IIB rheumatoid arthritis clinical trial using T cell receptor peptides
60. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis
61. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen
62. The effects of the treatment with anti-LFA-1a or anti-ICAM-1 mAb on the tolerance and autoimmunity in mice injected at birth with F1 hybrid cells depends on the saturation of these molecules in different lymphoid organs
63. Immunotherapy with antibodies to cell adhesion molecules in proteoglycan-induced arthritis
64. Blockade of vascular endothelial growth factor activity attenuates murine collagen-induced arthritis
65. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis
66. Adhesion molecules: A rheumatologic perspective
67. T cell receptor peptide vaccination in rheumatoid arthritis: A placebo controlled trial using a combination of Vb3, 14 and 17 peptides
68. Expression of IL-12 in synovial tissue from patients with RA
69. The expanding universe of T cell subsets: TH1, Th2 and more
70. Gene transfer for IL-10 into human synovial fi-broblasts and implantation into the SCID mouse
71. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen
72. Apoptosis and functional fas antigen in RA synoviocytes
73. Antibodies to interleukin 12 abrogate established experimental colitis in mice
74. Suppression of collagen induced arthritis by an angiogenesis inhibitor. AGM-1470, in combination with cyclosporin
75. Evidence for the effects of a superantigen in rheumatoid arthritis
76. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus
77. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice
78. Interleukin 4 and interleukin 10 are synergistic to inhibit cell-mediated immunity in vivo
79. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the fas apoptotic pathway
80. The type I IL-1 receptor acts in series with TNF-α to induce arthritis in TNF-α transgenic mice
81. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease
82. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery
83. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases
84. Immune complexes from SLE sera induce IL-10 production. A possible vicious circle maintaining B cell hyperactivity in SLE
85. Soluble IL-15 receptor alpha chain administration prevents murine collagen induced arthritis: A role for IL-15 in development of antigen induced immunopathology
86. Elevated TH1- or TH0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis, modulation by treatment with anti-ICAM-1 correlates with clinical benefit
87. Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis responding to treatment with a monoclonal antibody to CD54 (ICAM-1)
88. Synergistic inhibition of collagen induced arthritis through dual inhibition of ICAM-1 and CD40L pathways
89. Treatment of rheumatoid arthritis with a DR4/1 peptide
90. The future use of biological agents in combination for treatment of rheumatoid arthritis
91. T cell receptors in rheumatoid arthritis
92. Chemokines in rheumatoid arthritis
93. Proinflammatory and immunoregulatory functions of IL-12
94. Prevention and reversal of cartilage degradation in rheumatoid arthritis by IL-10 and IL-4
95. Mechanism of action of short term combination of CTLA4Ig/CD40L therapy in murine SLE
96. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
97. Subcutaneous administration of anti-C5 monoclonal antibody induces systemic complement inhibition and ameliorates immune complex mediated inflammatory responses
98. Periarticular gene therapy with viral IL-10 can prevent collagen-induced arthritis in mice
99. Anti-TNF meliorates joint disease in murine collagen induced arthritis
100. Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera
101. A placebo controlled trial of ICAM-1 antisense oligoneucleotide in the treatment of Crohn's disease
102. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides
103. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen
104. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand expressing APCs as a therapy of autoimmune disease
105. Requirement for TNF-α and IL-1α in fetal thymocyte commitment and differentiation